Your search for ‘Smart & Biggar’ returned 2,497 results

The arm of the law is indeed long. In its June 11, 2015 decision, the British Columbia Court of Appeal ("BCCA") upheld an injunction against Google, Inc. issued by the British Columbia Supreme Court...

On October 23, 2014, the Canadian Federal government introduced Bill C-43, an omnibus budget bill also known as the Economic Action Plan 2014 Act, No. 2.

On October 29, Canada's federal government tabled a second budget implementation bill that included a number of provisions relating to intellectual property, including a few proposed amendments

It has been 24 years since British scientists cloned Dolly the sheep, and now Brexit is about to give rise to an entirely different type of cloning.

Our predecessors have always been collectors. Hunter-gatherers survived in harsh climates by collecting stone axes, arrow- heads, animal furs and the like.

Recent Canadian court cases have provided insight into the scope of statutory "safe harbour" exemptions from patent infringement.

To be patentable, an invention must meet four main criteria: it must be new, it cannot be obvious, it must be useful and, crucially, it must fall within the definition of "invention"...

The Canadian Intellectual Property Office published on March 8, 2013, the revised examination guidelines for its patent examiners in the wake of the 2011 Federal Court of Appeal decision in Attorney General of Canada v. Amazon.com Inc.

A little over a year has passed since Canada overhauled its trademark legislation and acceded to the Madrid Protocol, making it easier than ever to protect trademark rights in Canada.

The Commissioner's Decision Re Genentech, Inc. (2021 CACP 8) is the most recent case to consider medical use claims following the clarification of patentable subject matter in the CIPO guidance...

A discussion on the exclusivity and protections of innovative drugs.

On June 29, 2016, the United States Patent and Trademark Office (USPTO) implemented a pilot program for expediting examination of patent applications relating to cancer immunotherapy.

In September 2017, the Patented Medicine Prices Review Board (PMPRB or Board) decided that Alexion's SOLIRIS (eculizumab) was sold at an excessive price.

On March 12, 2020, Justice Kane of the Federal Court broke new ground, applying the new Vavilov standard of review approach to a Trademark Opposition Board decision appeal for the first time...

The Federal Court of Canada recently issued a decision in AbbVie Corporation v. Janssen Inc.,2014 FC 55, involving infringement and validity of a biologic patent.

As previously reported, the Federal Court found Janssen's Canadian Patent No. 2,661,422 (422 patent)—which relates to treatment of prostate cancer in humans by co-administration...

The Federal Court released a pair of decisions in patent litigation relating to paliperidone palmitate (Janssen's INVEGA SUSTENNA): Janssen Inc v Pharmascience, 2022 FC 62 and Janssen Inc v Apotex, 2022 FC 107.